Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT06290349 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: DA5221-T1
DRUG: DA5221-T2
DRUG: Placebo
DRUG: DA5221-B1
DRUG: DA5221-B2

Sponsor

Dong-A ST Co., Ltd.